These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31037425)

  • 1. Current Treatment Options in Neurology-SMA Therapeutics.
    Waldrop MA; Kolb SJ
    Curr Treat Options Neurol; 2019 Apr; 21(6):25. PubMed ID: 31037425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
    Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
    J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I.
    Mirea A; Shelby ES; Axente M; Badina M; Padure L; Leanca M; Dima V; Sporea C
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
    Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
    Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
    Schwartz M; Likhite S; Meyer K
    Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Adult Spinal Muscular Atrophy: Overview and Recent Developments.
    Brakemeier S; Stolte B; Kleinschnitz C; Hagenacker T
    Curr Pharm Des; 2022; 28(11):892-898. PubMed ID: 35352647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 : Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM)].
    Ziegler A; Wilichowski E; Schara U; Hahn A; Müller-Felber W; Johannsen J; von der Hagen M; von Moers A; Stoltenburg C; Saffari A; Walter MC; Husain RA; Pechmann A; Köhler C; Horber V; Schwartz O; Kirschner J
    Nervenarzt; 2020 Jun; 91(6):518-529. PubMed ID: 32394004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges.
    Messina S; Sframeli M
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32668756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The respiratory impact of novel therapies for spinal muscular atrophy.
    Paul GR; Gushue C; Kotha K; Shell R
    Pediatr Pulmonol; 2021 Apr; 56(4):721-728. PubMed ID: 33098622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onasemnogene Abeparvovec: First Global Approval.
    Hoy SM
    Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination molecular therapies for type 1 spinal muscular atrophy.
    Harada Y; Rao VK; Arya K; Kuntz NL; DiDonato CJ; Napchan-Pomerantz G; Agarwal A; Stefans V; Katsuno M; Veerapandiyan A
    Muscle Nerve; 2020 Oct; 62(4):550-554. PubMed ID: 32710634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs.
    Ballreich J; Ezebilo I; Khalifa BA; Choe J; Anderson G
    J Manag Care Spec Pharm; 2022 Jan; 28(1):39-47. PubMed ID: 34949120
    [No Abstract]   [Full Text] [Related]  

  • 13. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2020 Update to Spinal Muscular Atrophy Management in Saudi Arabia.
    Bashiri FA; Temsah MH; Hundallah K; Alsohime F; AlRuthia Y
    Front Pediatr; 2021; 9():684134. PubMed ID: 34136444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
    Al-Zaidy SA; Mendell JR
    Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
    Connock M; Andronis L; Auguste P; Dussart C; Armoiry X
    Expert Opin Biol Ther; 2020 Jul; 20(7):823-827. PubMed ID: 32434404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
    Malone DC; Dean R; Arjunji R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Dabbous O
    J Mark Access Health Policy; 2019; 7(1):1601484. PubMed ID: 31105909
    [No Abstract]   [Full Text] [Related]  

  • 18. Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series.
    Alves CRR; Petrillo M; Spellman R; Garner R; Zhang R; Kiefer M; Simeone S; Sohn J; Eichelberger EJ; Rodrigues E; Arruda EA; Townsend EL; Farwell W; Swoboda KJ
    Mol Ther Methods Clin Dev; 2021 Dec; 23():524-538. PubMed ID: 34853799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy.
    Ramos-Platt L; Elman L; Shieh PB
    Int J Gen Med; 2022; 15():7341-7353. PubMed ID: 36157294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen for the treatment of spinal muscular atrophy.
    Chiriboga CA
    Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.